Portal de Periódicos da CAPES

Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition

2019; Wiley; Volume: 146; Issue: 12 Linguagem: Inglês

10.1002/ijc.32674

1097-0215

Iris Cervenka, Marie Al Rahmoun, Yahya Mahamat‐Saleh, A. Fournier, Marie‐Christine Boutron‐Ruault, Gianluca Severi, Saverio Caini, Domenico Palli, Reza Ghiasvand, Marit B. Veierød, Edoardo Botteri, Anne Tjønneland, Anja Olsen, Renée T. Fortner, Rudolf Kaaks, Matthias B. Schulze, Salvatore Panico, Antonia Trichopoulou, Clio Dessinioti, Katerina Niforou, Sabina Sieri, ­Rosario ­Tumino, Carlotta Sacerdote, Bas Bueno‐de‐Mesquita, Torkjel M. Sandanger, Sandra Colorado‐Yohar, María‐José Sánchez, Leire Gil Majuelo, Leila Luján‐Barroso, Eva Ardanáz, Susana Merino, Karolin Isaksson, Salma Butt, Ingrid Ljuslinder, Malin Jansson, Ruth C. Travis, Kay‐Tee Khaw, Elisabete Weiderpass, Laure Dossus, Sabina Rinaldi, Marina Kvaskoff,

melanin and skin pigmentation

Evidence suggests an influence of sex hormones on cutaneous melanoma risk, but epidemiologic findings are conflicting. We examined the associations between use of oral contraceptives (OCs) and menopausal hormone therapy (MHT) and melanoma risk in women participating in the European Prospective Investigation into Cancer and Nutrition (EPIC). EPIC is a prospective cohort study initiated in 1992 in 10 European countries. Information on exogenous hormone use at baseline was derived from country-specific self-administered questionnaires. We used Cox proportional hazards regression models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Over 1992-2015, 1,696 melanoma cases were identified among 334,483 women, whereof 770 cases among 134,758 postmenopausal women. There was a positive, borderline-significant association between OC use and melanoma risk (HR = 1.12, 95% CI = 1.00-1.26), with no detected heterogeneity across countries (p